

Jing Xue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6756323/publications.pdf>

Version: 2024-02-01

32
papers

2,492
citations

516215

16
h-index

454577

30
g-index

34
all docs

34
docs citations

34
times ranked

5964
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. <i>Cell</i> , 2022, 185, 131-144.e18.	13.5	24
2	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 38-48.	1.1	3
3	Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection. <i>Viruses</i> , 2022, 14, 581.	1.5	7
4	A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile. <i>Pharmaceuticals</i> , 2022, 15, 424.	1.7	0
5	Protocol for evaluating CD8+ T cell-mediated immunity in latently SHIV-infected rhesus macaques with HIV fusion-inhibitory lipopeptide monotherapy. <i>STAR Protocols</i> , 2022, 3, 101479.	0.5	0
6	Therapeutic effect of (5R)-5-hydroxytryptolide (LLDT-8) in SIV infected rhesus monkeys. <i>International Immunopharmacology</i> , 2022, 110, 108932.	1.7	1
7	Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats. <i>Journal of Infectious Diseases</i> , 2021, 223, 1313-1321.	1.9	46
8	SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice. <i>Animal Models and Experimental Medicine</i> , 2021, 4, 2-15.	1.3	17
9	Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 200.	7.1	41
10	Stage-Dependent Within-Individual Comparison Reveals SIV-Specific Activation/Exhaustion Shift in Rhesus Macaques. <i>Frontiers in Microbiology</i> , 2021, 12, 704449.	1.5	2
11	SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 337.	7.1	157
12	Probiotics protect against tenofovir-induced mandibular bone loss in mice by rescuing mandible-derived mesenchymal stem cell proliferation and osteogenic differentiation. <i>Journal of Oral Rehabilitation</i> , 2020, 47, 83-90.	1.3	11
13	The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. <i>Nature</i> , 2020, 583, 830-833.	13.7	992
14	Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. <i>Nature Communications</i> , 2020, 11, 4400.	5.8	161
15	Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 66.	7.1	38
16	Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	3
17	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	10
18	Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. <i>Science</i> , 2020, 369, 818-823.	6.0	416

#	ARTICLE	IF	CITATIONS
19	Age-related rhesus macaque models of COVID-19. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 93-97.	1.3	238
20	Does Mucosal B1 Activation Result in the Accumulation of Peak IgM During Chronic Intrarectal SIVmac239 Exposure to Protect Chinese-Origin Rhesus Macaques From Disease Progression?. <i>Frontiers in Microbiology</i> , 2020, 11, 357.	1.5	1
21	SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters. <i>Frontiers in Microbiology</i> , 2020, 11, 618891.	1.5	46
22	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice. <i>Journal of Infectious Diseases</i> , 2020, 222, 551-555.	1.9	61
23	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	1.5	8
24	<i>Lactobacillus rhamnosus</i> GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice via gut-microbiota-dependent anti-inflammation. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986065.	1.1	27
25	CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques. <i>Nature Communications</i> , 2019, 10, 2257.	5.8	18
26	Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. <i>PLoS Pathogens</i> , 2019, 15, e1007552.	2.1	30
27	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008082.	2.1	16
28	Construction of a comprehensive observer-based scale assessing aging-related health and functioning in captive rhesus macaques. <i>Aging</i> , 2019, 11, 6892-6903.	1.4	1
29	Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models. <i>Journal of Virology</i> , 2018, 92, .	1.5	29
30	A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity. <i>Journal of Virology</i> , 2017, 91, .	1.5	53
31	Efficient Transduction of Human and Rhesus Macaque Primary T Cells by a Modified Human Immunodeficiency Virus Type 1-Based Lentiviral Vector. <i>Human Gene Therapy</i> , 2017, 28, 271-285.	1.4	7
32	Deglycosylation of FcγR at N58 increases its binding to IgA. <i>Glycobiology</i> , 2010, 20, 905-915.	1.3	28